N-[2-[ethyl-[2-(2-fluoropyridin-3-yl)oxyethyl]amino]ethyl]-6-(125I)iodanylimidazo[1,2-a]pyridine-2-carboxamide | 1288843-96-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: N-[2-[ethyl-[2-(2-fluoropyridin-3-yl)oxyethyl]amino]ethyl]-6-(125I)iodanylimidazo[1,2-a]pyridine-2-carboxamide
• CAS: 1288843-96-8
• 化学式: C₁₉H₂₁FIN₅O₂
• 分子量: 495.406
• InChiKey: QOIIIFBGLUAORX-OJSTVIJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[2-[ethyl-[2-(2-fluoropyridin-3-yl)oxyethyl]amino]ethyl]-6-(125I)iodanylimidazo[1,2-a]pyridine-2-carboxamide 在 盐酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 [(125)I]N-[2-[N-ethyl-N-[2-(2-fluoropyridin-3-yloxy)ethyl]amino]ethyl]-6-iodoimidazo[1,2-a]pyridine-2-carboxamide dihydrochloride
  参考文献：
  名称：

  Single Photon Emission Computed Tomography/Positron Emission Tomography Imaging and Targeted Radionuclide Therapy of Melanoma: New Multimodal Fluorinated and Iodinated Radiotracers

  摘要：

  This study reports a series of 14 new iodinated and fluorinated compounds offering both early imaging (I-123, I-124, F-18) and systemic treatment (I-131) of melanoma potentialities. The biodistribution of each I-125-labeled tracer was evaluated in a model of melanoma B16F0 bearing mice, using in vivo serial gamma scintigraphic imaging. Among this series, [I-125]56 emerged as the most promising compound in terms of specific tumoral uptake and in vivo kinetic profile. To validate our multimodality concept, the radiosynthesis of [F-18]56 was then optimized and this radiotracer has been successfully investigated for in vivo PET imaging of melanoma in B16F0- and B16F10-bearing mouse model. The therapeutic efficacy of [I-131]56 was then evaluated in mice bearing subcutaneous B16F0 melanoma, and a significant slow down in tumoral growth was demonstrated. These data support further development of 56 for PET imaging (F-18, I-124) and targeted radionuclide therapy (I-131) of melanoma using a single chemical structure.

  DOI：

  10.1021/jm101574q
• 作为产物：
  描述：

  N-[2-[N-ethyl-N-[2-(2-fluoropyridin-3-yloxy)ethyl]amino]ethyl]-6-iodoimidazo[1,2-a]pyridine-2-carboxamide 在 四(三苯基膦)钯 、 六正丁基二锡 、 sodium iodide 、 chloroamine-T 作用下， 以 甲苯 、 乙醇 为溶剂， 反应 12.5h， 生成 N-[2-[ethyl-[2-(2-fluoropyridin-3-yl)oxyethyl]amino]ethyl]-6-(125I)iodanylimidazo[1,2-a]pyridine-2-carboxamide
  参考文献：
  名称：

  Single Photon Emission Computed Tomography/Positron Emission Tomography Imaging and Targeted Radionuclide Therapy of Melanoma: New Multimodal Fluorinated and Iodinated Radiotracers

  摘要：

  This study reports a series of 14 new iodinated and fluorinated compounds offering both early imaging (I-123, I-124, F-18) and systemic treatment (I-131) of melanoma potentialities. The biodistribution of each I-125-labeled tracer was evaluated in a model of melanoma B16F0 bearing mice, using in vivo serial gamma scintigraphic imaging. Among this series, [I-125]56 emerged as the most promising compound in terms of specific tumoral uptake and in vivo kinetic profile. To validate our multimodality concept, the radiosynthesis of [F-18]56 was then optimized and this radiotracer has been successfully investigated for in vivo PET imaging of melanoma in B16F0- and B16F10-bearing mouse model. The therapeutic efficacy of [I-131]56 was then evaluated in mice bearing subcutaneous B16F0 melanoma, and a significant slow down in tumoral growth was demonstrated. These data support further development of 56 for PET imaging (F-18, I-124) and targeted radionuclide therapy (I-131) of melanoma using a single chemical structure.

  DOI：

  10.1021/jm101574q